Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Inclusion Criteria: * Signed informed consent * Male or female patient ≥ 18 years of age * Classification of Sjögren's Syndrome according to ACR/EULAR 2016 criteria (Shiboski et al 2017) * Seropositive for anti-Ro/SSA antibodies * Stimulated whole salivary flow rate of ≥ 0.1 mL/min Inclusion criteria specific for Cohort 1: * ESSDAI ≥ 5 within the 8 predefined organ domains * ESSPRI score of ≥5 Inclusion criteria specific for Cohort 2: * ESSDAI \< 5 within 8 domains scored for inclusion criterion for Cohort 1 * ESSPRI fatigue subscore ≥ 5 or ESSPRI dryness subscore ≥ 5 Exclusion Criteria: * Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic disease constitutes the principle illness * Use of other investigational drugs * Prior use of B cell depleting therapies, abatacept or any other immunosuppressants unless specifically allowed be the protocol. * Use of steroids at dose \>10 mg/day. * Uncontrolled ocular rosacea (affecting the eye adnexa), posterior blepharitis or Meibomian gland disease (this criterion applies only to patients considered for Cohort 2) * Active viral, bacterial or other infections requiring systemic treatment * Receipt of live/attenuated vaccine within a 2-month period prior to randomization. * Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). * Evidence of active tuberculosis (TB) infection.